Dr. Krop is a clinical translational medical oncologist whose primary research focuses on understanding and overcoming mechanisms of resistance to HER2-directed therapies. Dr. Krop played a major role in developing T-DM1 (Kadcyla or trastuzumab emtansine), a new targeted therapy for HER2-positive breast cancers, including metastatic breast cancer. Dr. Krop was also a Principle Investigator for the phase 2 DESTINY-breast01 trial, which evaluated the HER2-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive breast cancer. The FDA granted accelerated approval for this treatment in December of 2019 based on the results of the DESTINY-breast01 trial. The drug will be marketed as Enhertu.
Dr. Krop completed his medical training and residency at Johns Hopkins University School of Medicine, Internal Medicine, followed by a fellowship at Dana-Farber/Partners CancerCare, Hematology/Oncology. Dr. Krop received his board certification in internal medicine in 1999 and in medical oncology in 2002.
Dr. Krop is currently leading several clinical trials exploring combinations of novel targeted therapies and immune therapies designed to overcome resistance to HER2-directed agents. Dr. Krop’s Komen-funded research supports a project that seeks to understand how breast tumors and metastatic tumors from patients with HER2-positive breast cancer become resistant to HER2-targeted therapies.